Safety of denosumab in giant-cell tumour of bone.

摘要

In The Lancet Oncology, Athanassios Kyrgidis and Konstantinos Toulis commented on the study of denosumab for the treatment of giant-cell tumour of bone.2 While recognising the potential of denosumab therapy for the treatment of giant-cell tumour, Kyrgidis and Toulis discuss the adequacy of safety follow-up in this study, and make suggestions for the detection of osteonecrosis of the jaw (ONJ). They specifically recommend protocol amendments-which incorporate regular dental assessment-to monitor for either ONJ or implementation of measures to prevent ONJ. ONJ is a potential concern for patients who are treated with antiresorptive therapies, including bisphosphonates and denosumab.